Why This Beaten-Down Cannabis Giant is a Table-Pounding Buy

By Keith Speights – Apr 16, 2026 at 4:44AM ESTKey PointsGreen Thumb Industries' financials are strong with growing revenue and earnings and plenty of cash.The company has an upcoming catalyst related to the rescheduling of marijuana.Analysts think Green Thumb's stock could soar over the next 12 months.Some investors might give Green Thumb Industries (GTBIF +5.92%) a green thumb down these days. The multi-state cannabis operator's share price is down by a double-digit percentage year to date. Green Thumb's stock is also more than 80% below its peak set in early 2021. However, the company remains one of the top players in the U.S. cannabis market, with 113 dispensaries and operations in 14 states. Here's why Green Thumb is a table-pounding buy. Image source: Getty Images. Financially strong with an upcoming catalyst Marijuana stocks, in general, are struggling right now. A supply demand imbalance persists in the U.S., with declining prices exerting significant financial pressure. Many cannabis operators continue to lose money. But not Green Thumb. The Illinois-based company generated $1.2 billion in revenue for 2025. Its earnings topped $114 million last year. Green Thumb's fourth quarter was even stronger, with revenue rising 5.7% year over year to $311.1 million and net income of $83.2 million. Sure, earnings numbers can sometimes be misleading due to accounting tricks. That isn't the case with Green Thumb, though. Cash flow isn't as easily manipulated. Green Thumb generated cash flow from operations of roughly $295 million in 2025. The company's balance sheet is solid. Green Thumb's cash position stood at $274.3 million at the end of 2025. The cannabis operator also recently increased its existing syndicated credit facility by $50 million. Founder and CEO Ben Kovler said, "Adding $50 million to our balance sheet at a low rate should be good for our shareholders long term." A promising catalyst should be right around the corner for Green Thumb. President Trump signed an executive order in December 2025 that directed the U.S. Attorney General to expedite the rescheduling of cannabis to Schedule III, which includes drugs "with a moderate to low potential for physical and psychological dependence." This rescheduling will effectively lift the IRS Section 280E restrictions on companies that sell Schedule I or II drugs, allowing them to deduct ordinary business expenses. Green Thumb's bottom line should benefit significantly once rescheduling is finalized. ExpandOTC: GTBIFGreen Thumb IndustriesToday's Change(5.92%) $0.40Current Price$7.16Key Data PointsMarket Cap$1.7BDay's Range$6.64 - $7.1652wk Range$4.80 - $10.43Volume247KAvg Vol585KGross Margin45.90% Pounding the table All eight analysts surveyed by S&P Global (NYSE: SPGI) in April who cover Green Thumb rated the stock a buy. The consensus 12-month price target for the stock implies roughly 169% upside. Sure, Green Thumb's stock is likely to remain volatile. That comes with the territory when you invest in marijuana stocks. But with its solid financials and a catalyst on the way that will boost earnings, I think the analysts are right: Green Thumb is a stock worthy of pounding the table for aggressive investors. Read NextApr 13, 2026 •By Keith SpeightsBest Marijuana Stocks for 2026 and How to InvestMar 18, 2026 •By Keith SpeightsBest CBD Stocks for 2026 and How to InvestApr 16, 2026 •By Prosper Junior BakinyThis Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?Apr 16, 2026 •By Adria CiminoPrediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug MarketApr 15, 2026 •By Prosper Junior Bakiny2 Healthcare Stocks to Buy and 1 to Approach With CautionApr 16, 2026 •By Harsh Chauhan2 Super Semiconductor Stocks for the Next Stage of the AI Supercycle.

Buy Them Before They Soar by 74% to 81%.About the AuthorKeith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.TMFFishBizStocks MentionedGreen Thumb IndustriesOTC: GTBIF$7.16(+5.92%)+$0.40S&P GlobalNYSE: SPGI$430.58(+1.26%)+$5.34*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.